Zoldonrasib

Zoldonrasib (RMC-9805) is a potent and orally active KRAS G12D inhibitor.Zoldonrasib induces apoptosis in KRAS G12D mutant cancer cells. Zoldonrasib has the potential for the research of KRAS G12D mutant cancer[1][2].

Product Specifications

CAS Number

[2922732-54-3]

Product Name Alternative

RMC-9805; KRAS G12D inhibitor 18

UNSPSC

12352005

Target

Apoptosis; Ras

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; MAPK/ERK Pathway

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/kras-g12d-inhibitor-18.html

Purity

99.73

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C([C@H]1NN(C([C@@H](NC([C@@H](N2C[C@]3(CN(C([C@@H]4N(C)[C@@H]4C5CC5)=O)CC3)CC2)C6CCCC6)=O)C[C@H]7CN8CCO7)=O)CCC1)OCC(C)(C)CC9=[C@@]([C@@]%10=C([C@@H](OC)C)N=CC(N%11CCN(C%12CC%12)CC%11)=C%10)N(CC(F)(F)F)C%13=C9C=C8C=C%13

Molecular Formula

C63H88F3N11O7

Molecular Weight

1168.44

References & Citations

[1]BLAKE JAMES F, et al. Preparation of peptide-linked macrocyclic dipeptides as Ras inhibitors.World Intellectual Property Organization, WO2023060253 A1 2023-04-13|[2]Knox, J et al.RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D (ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models. Cancer Res 1 April 2023; 83 (7_Supplement) : 3475|[3]John E. Knox, et al. Discovery of RMC-9805, an Oral, RAS (ON) G12D-Selective Covalent Tri-Complex Inhibitor.